Cargando…

Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment

To study the changes in human epidermal growth factor receptor 2 (HER2) expression in patients with HER2-positive breast cancer before and after neoadjuvant treatment. The clinicopathologic data of 499 patients with HER2-positive breast cancer who completed neoadjuvant treatment and surgery at the F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Xiaofei, Zhang, Xiangmei, Ma, Xiangmin, Yang, Chao, Li, Jingping, Liu, Beichen, Shi, Chao, Liu, Yunjiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	5750
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545330/ https://www.ncbi.nlm.nih.gov/pubmed/37773875 http://dx.doi.org/10.1097/MD.0000000000034903

Ejemplares similares

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab
por: Wang, Xinle, et al.
Publicado: (2019)

Diagnosis and treatment of advanced HER2-positive breast cancer in young pregnant female: A case report
por: Tang, Tiantian, et al.
Publicado: (2020)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023)

Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: A case report
por: Cao, Yong, et al.
Publicado: (2019)

Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction
por: Wu, Wei, et al.
Publicado: (2016)

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
por: García, Francisco José Valdivia, et al.
Publicado: (2020)

Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Choi, Ji Soo, et al.
Publicado: (2016)

Prognostic significance of preoperative albumin to fibrinogen ratio associated nomograms in patients with breast invasive ductal carcinoma
por: Zheng, Lihua, et al.
Publicado: (2020)

Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports
por: Yang, Haisong, et al.
Publicado: (2017)

Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer
por: Chen, Jim-Ray, et al.
Publicado: (2017)

HER2-positive pure mucinous breast carcinoma: A case report and literature review
por: Zhao, Xingjuan, et al.
Publicado: (2020)

Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis
por: Lin, Yuxiang, et al.
Publicado: (2020)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival
por: Erol, Timuçin, et al.
Publicado: (2019)

Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study
por: Aksoy, Suleyman Ozkan, et al.
Publicado: (2020)

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
por: Ma, Hong-Fang, et al.
Publicado: (2023)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis
por: Liu, Jiamin, et al.
Publicado: (2021)

Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study
por: Wu, Jiangwen, et al.
Publicado: (2022)

Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
por: Tasdoven, Ilhan, et al.
Publicado: (2022)

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study
por: Yang, Xuan, et al.
Publicado: (2022)

Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
por: Ma, Xiangmin, et al.
Publicado: (2022)

Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis
por: Hu, Jianxin, et al.
Publicado: (2017)

Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer: A systematic review and meta-analysis
por: Xu, Han-Xiao, et al.
Publicado: (2016)

Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer: A SEER-based study
por: Li, Yang, et al.
Publicado: (2021)

Conditional disease-free survival among patients with breast cancer
por: Paik, Hyun-June, et al.
Publicado: (2017)

The relative effect of mammographic screening on breast cancer mortality by socioeconomic status
por: Ripping, Theodora M., et al.
Publicado: (2016)

The Extent of Axillary Surgery Is Associated With Breast Cancer-specific Survival in T1–2 Breast Cancer Patients With 1 or 2 Positive Lymph Nodes: A SEER-Population Study
por: Li, Shunrong, et al.
Publicado: (2016)

Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients
por: Han, Hyun Ho, et al.
Publicado: (2016)

Assessment of Invasive Breast Cancer Heterogeneity Using Whole-Tumor Magnetic Resonance Imaging Texture Analysis: Correlations With Detailed Pathological Findings
por: Ko, Eun Sook, et al.
Publicado: (2016)

Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis
por: Jiang, Mengjie, et al.
Publicado: (2021)

Anemia and thrombocytopenia as initial symptoms of occult breast cancer with bone marrow metastasis: A case report
por: Liu, Lulu, et al.
Publicado: (2017)

Impact of WNT1-inducible signaling pathway protein-1 (WISP-1) genetic polymorphisms and clinical aspects of breast cancer
por: Wang, Yan, et al.
Publicado: (2019)

The duration of endocrine therapy and breast cancer patients’ survival: A nationwide population-based cohort study
por: Chang, Chuan-Hsun, et al.
Publicado: (2019)

Association of neutrophil-to-lymphocyte ratio with clinical, pathological, radiological, laboratory features and disease outcomes of invasive breast cancer patients: A retrospective observational cohort study
por: Jadoon, Sarosh Khan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k5uog6t7gabelpug4s2a14meul